Emetine compounds for treatment and prevention of flavivirus infection

US10555942B2 · kind B2 · utility

Assignees

• Florida State University Research Foundation, Inc. · US
• THE JOHNS HOPKINS UNIVERSITY · US
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Hengli Tang · Tallahassee, US
• Emily M. Lee · Tallahassee, US
• Anil Mathew Tharappel · Tallahassee, US
• Hongjun Song · Madison, US
• Guo-li Ming · Village of La Jolla, US
• Wei Zheng · Rockville, US
• Miao Xu · Hangzhou City, CN
• Shu-Ping Yang · Alpharetta, US
• Ruili Huang · Rockville, US
• Wenwei Huang · Rockville, US
• Khalida Shamim · Gaithersburg, US
• Hao Li · Brookline, US

Key dates

• Filing date: Oct 10, 2018
• Grant date: Feb 11, 2020
• Expiry date: Oct 10, 2038

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.